Focus: Pierre Fabre is a French specialty pharmaceutical company founded in 1962, focused on oncology and dermatology/cosmetics with a diversified but revenue-concentrated portfolio.
Profile data last refreshed Yesterday · AI intelligence enriched 1w ago
Hot — 270 jobs added in 30d
Net +116 (270 new, 154 removed). Aggressive expansion phase.
Best suited for R&D scientists and oncology specialists willing to accept near-term regulatory uncertainty in exchange for emerging pipeline exposure; commercial/operational roles face restructuring risk post-HEMANGEOL LOE.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Pierre Fabre
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Pierre Fabre's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Company's sole disclosed revenue source; mechanism of action not fully understood; patent cliff creates urgent need for pipeline transition.
Vinca alkaloid with established oncology franchise but approaching exclusivity loss; Phase 2 breast cancer study ongoing.
Generic chemotherapy agent (ANDA approval); topoisomerase II inhibitor with mature market profile; minimal differentiation opportunity.
Dental local anesthetic; vasoconstrictor formulation extends duration; outside core oncology/dermatology focus.
2 discontinued, 0 duplicate formulations not shown
Pierre Fabre’s Braftovi gains CHMP positive opinion for mCRC - Pharmaceutical Technology
Pierre Fabre’s Braftovi gains CHMP positive opinion for mCRC Pharmaceutical Technology
Pierre Fabre outlines FDA path forward for tabelecleucel after setback - The Pharma Letter
Pierre Fabre outlines FDA path forward for tabelecleucel after setback The Pharma Letter
Pierre Fabre Pharmaceuticals Announces Regulatory Update Following Type A Meeting with U.S. Food and Drug Administration (FDA) on Tabelecleucel Biologic License Application (BLA) - PR Newswire
Pierre Fabre Pharmaceuticals Announces Regulatory Update Following Type A Meeting with U.S. Food and Drug Administration (FDA) on Tabelecleucel Biologic License Application (BLA) PR Newswire
FDA to reconsider shock rejection of cell therapy Ebvallo. Could uniQure be next? - Fierce Pharma
FDA to reconsider shock rejection of cell therapy Ebvallo. Could uniQure be next? Fierce Pharma
Pierre Fabre to boost investment in China - China Daily
Pierre Fabre to boost investment in China China Daily
Atara Biotherapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Operational Progress - BioSpace
Atara Biotherapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Operational Progress BioSpace
Showing 6 of 10 news items
Based on last 4 crawl cycles
Recent peer-reviewed publications with author affiliations at this company
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo